Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform
Acquiring Company
Bristol Myers Squibb
Acquired Company
RayzeBio, Inc.
PrincetonSan DiegoManufacturingBiotechnologyProfessional ServicesHealth CareMedicalTherapeuticsPharmaceuticalLegalBiopharmaLaw EnforcementBiotechnologyDescription
Bristol Myers Squibb has successfully completed the acquisition of RayzeBio, Inc., a biopharmaceutical company known for its pioneering work in the development of radiopharmaceutical therapeutics (RPTs) for the treatment of solid tumors. This acquisition bolsters Bristol Myers Squibb's oncology pipeline, particularly in the area of RPTs, and is expected to unlock new opportunities for growth and innovation in the coming years.
Quick answer
Bristol Myers Squibb is acquiring RayzeBio, Inc., announced February 26, 2024. Bristol Myers Squibb is based in Princeton, New Jersey, United States.
- Who acquired RayzeBio, Inc?
- Bristol Myers Squibb agreed to acquire RayzeBio, Inc. on February 26, 2024.
- How much did Bristol Myers Squibb pay for RayzeBio, Inc?
- The deal value was not disclosed.
- What does Bristol Myers Squibb do?
- Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
- Where are Bristol Myers Squibb and RayzeBio, Inc. based?
- Bristol Myers Squibb is based in Princeton, New Jersey, United States. RayzeBio, Inc. is based in San Diego, California, United States.
- Who are the decision-makers at Bristol Myers Squibb?
- Fundz holds 2 contacts at Bristol Myers Squibb. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Professional Services and Medical
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Bristol Myers Squibb completes acquisition of Karuna Therapeutics, Inc. to strengthen its neuroscience portfolio (March 18, 2024)
- Abbvie To Acquire Landos Biopharma, Further Strengthening Its Portfolio In Inflammatory And Autoimmune Diseases (March 25, 2024)
- Bristol Myers Squibb Completes Acquisition of Mirati Therapeutics, Strengthening and Diversifying Oncology Portfolio (January 23, 2024)
- Nuvation Bio Inc. completes acquisition of AnHeart Therapeutics Ltd. to enhance its oncology pipeline (April 10, 2024)
- Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction (March 25, 2024)
- Juvisé Pharmaceuticals acquires rights to MS therapy Ponvory outside North America (April 2, 2024)
Who to call at Bristol Myers Squibb, and when
When Bristol Myers Squibb changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Bristol Myers Squibb raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Bristol Myers Squibb, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Bristol Myers Squibb. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Bristol Myers Squibb makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired RayzeBio, Inc.?
RayzeBio, Inc. was acquired by Bristol Myers Squibb, based in Princeton. The deal was reported on February 26, 2024. Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Bristol Myers Squibb is publicly traded (BMY) and operates in Manufacturing.
When did Bristol Myers Squibb acquire RayzeBio, Inc.?
Bristol Myers Squibb's acquisition of RayzeBio, Inc. was reported on February 26, 2024. Bristol Myers Squibb has successfully completed the acquisition of RayzeBio, Inc., a biopharmaceutical company known for its pioneering work in the development of radiopharmaceutical therapeutics (RPTs) for the treatment of solid tumors. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does RayzeBio, Inc. do?
RayzeBio Inc. is now part of Bristol Myers Squibb. Follow our progress delivering breakthrough therapies through our differentiated radiopharmaceutical platform @Bristol Myers Squibb or www.bms.com It is privately held, operating in Biotechnology, and is based in San Diego.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.